AstraZeneca Covid-19 vaccine shows 92% efficacy against Delta variant
According to the new data, the AstraZeneca Covid-19 vaccine is 92% effective against the Delta variant, and 86%…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
16 Jun 21
According to the new data, the AstraZeneca Covid-19 vaccine is 92% effective against the Delta variant, and 86%…
15 Jun 21
iTeos will receive an upfront payment of $625m, along with milestone payments of up to $1.45bn, in addition…
15 Jun 21
The Phase 3 PREVENT-19 study also met the key secondary endpoint of 100% efficacy against variants not considered…
14 Jun 21
The partnership with Tabuk will expand the global access to Moderna’s vaccine and supports the Covid-19 vaccine availability…
14 Jun 21
Novavax vaccine against Beta (B.1.351) variant virus showed a high immunogenic response in mice and produced neutralising antibodies
11 Jun 21
Verona is currently studying ensifentrine in a global Phase 3 programme in the US, Europe and South Korea,…
11 Jun 21
The approval of Epclusa for younger hepatitis C patients is based on the data from a Phase 2…
10 Jun 21
The US government is committed to buy around 1.7 million courses of molnupiravir upon FDA Emergency Use Authorisation…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
10 Jun 21
Trikafta was previously approved in the US to treat cystic fibrosis in 12 years and older people with…
09 Jun 21
Prevnar 20 is the first conjugate vaccine approved to protect against 20 types of invasive pneumococcal diseases and…